| 生物活性 | Jaceosidin is a flavonoid isolated fromArtemisia vestita, inducesapoptosisincancercells, activatesBaxand down-regulatesMcl-1and c-FLIP expression[1]. Jaceosidin exhibits anti-cancer[2], anti-inflammatory activities, decreases leves of inflammatory markers, and suppressesCOX-2expression andNF-κBactivation[3]. |
| IC50& Target[1][3] | |
体外研究
(In Vitro) | Jaceosidin (30, 50, 75 μM) induces apoptosis in human renal carcinoma Caki cells after treatment for 24 h, shows no obvious effect on normal cells[1].
Jaceosidin (75 μM) reduces MMP levels and causes cytochrome c release into the cytoplasm through Bax activation[1].
Jaceosidin-mediated apoptosis is involved in downregulation of Mcl-1, c-FLIP expression, which is via inhibition of NF-κB and/or Sp1 transcriptional activity[1].
Jaceosidin shows cytostatic activity to HES and HESC cells with IC50s of 52.68 and 55.10 μM, and is less cytotocxic on Hec1 A and KLE (IC50, 70.54, 147.14 μM, respectively), after treatment for 48 h[2].
Cell Viability Assay[2] | Cell Line: | Hec1A, KLE, HES and HESC cells | | Concentration: | 3.125, 6.25, 12.5, 25, 50, and 100 μM | | Incubation Time: | 48 hour | | Result: | Showed cytostatic activity to HES and HESC cells with IC50s of 52.68 and 55.10 μM, less cytotocxic on Hec1 A and KLE (IC50, 70.54, 147.14 μM). |
|
体内研究
(In Vivo) | Jaceosidin (10 and 20 mg/kg, p.o., once a day for 3 days) blocks carrageenan-induced increase in leukocyte number and protein levels in air pouch exudates in mice[3].
Jaceosidin (10, 20 mg/kg, p.o.) suppresses COX-2 expression and NF-κB activation in mice[3].
Jaceosidin (20 mg/kg, p.o. for 2 hours) reduces hind paw edema volume in rats[3].
| Animal Model: | 5-week-old male BALB/c mice (23-26 g)[3] | | Dosage: | 10 and 20 mg/kg | | Administration: | P.O. once a day for 3 days | | Result: | Decreased the volumes of exudates (inflammatory markers), cell number and protein levels. Inhibited TNF-α by 46.7% and 50.8%, IL-1β by 46.0% and 44.7%, and PGE2 by 21.7% and 16.9%, respectively, at 20 mg/kg. Blocked COX-2 expression and NF-κB activation. |
| Animal Model: | Male Sprague-Dawley rats (180-200 g)[3] | | Dosage: | 20 mg/kg | | Administration: | P.O., for 2 hour | | Result: | Reduced hind paw edema volume by 27.1% at 1 h, and 24.0% at 2 h, respectively. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Compositae
- Artemisia vestitaWall. ex Bess.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 125 mg/mL(378.46 mM;Need ultrasonic) Ethanol : 7.14 mg/mL(21.62 mM;Need ultrasonic) 配制储备液 | 1 mM | 3.0276 mL | 15.1382 mL | 30.2764 mL | | 5 mM | 0.6055 mL | 3.0276 mL | 6.0553 mL | | 10 mM | 0.3028 mL | 1.5138 mL | 3.0276 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (6.30 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.30 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (6.30 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.30 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (6.30 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.30 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com